European Commission approves Keytruda plus chemotherapy as neoadjuvant treatment for breast cancer
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Subscribe To Our Newsletter & Stay Updated